522 related articles for article (PubMed ID: 16773706)
41. [Cholestatic liver diseases].
Thimme R; Opitz OG; Blum HE; Kreisel W
Ther Umsch; 2004 Aug; 61(8):521-7. PubMed ID: 15457969
[TBL] [Abstract][Full Text] [Related]
42. Heart and bile acids - Clinical consequences of altered bile acid metabolism.
Vasavan T; Ferraro E; Ibrahim E; Dixon P; Gorelik J; Williamson C
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1345-1355. PubMed ID: 29317337
[TBL] [Abstract][Full Text] [Related]
43. Overlap syndromes.
Beuers U; Rust C
Semin Liver Dis; 2005 Aug; 25(3):311-20. PubMed ID: 16143946
[TBL] [Abstract][Full Text] [Related]
44. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
[TBL] [Abstract][Full Text] [Related]
45. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
[TBL] [Abstract][Full Text] [Related]
46. Primary sclerosing cholangitis.
Stiehl A; Benz C; Sauer P
Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
[TBL] [Abstract][Full Text] [Related]
47. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
48. Vanishing bile duct syndrome in a Hodgkin's lymphoma patient with fatal outcome despite lymphoma remission.
Aleem A; Al-Katari M; Alsaleh K; AlSwat K; Al-Sheikh A
Saudi J Gastroenterol; 2013; 19(6):286-9. PubMed ID: 24195983
[TBL] [Abstract][Full Text] [Related]
49. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
Polzien F; Ramadori G
J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
[TBL] [Abstract][Full Text] [Related]
50. Recent insights in primary sclerosing cholangitis.
Ponsioen CY
J Dig Dis; 2012 Jul; 13(7):337-41. PubMed ID: 22713082
[TBL] [Abstract][Full Text] [Related]
51. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
52. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
53. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
54. Use of ursodeoxycholic acid in liver diseases.
Kumar D; Tandon RK
J Gastroenterol Hepatol; 2001 Jan; 16(1):3-14. PubMed ID: 11206313
[TBL] [Abstract][Full Text] [Related]
55. Primary sclerosing cholangitis: updates in diagnosis and therapy.
Portincasa P; Vacca M; Moschetta A; Petruzzelli M; Palasciano G; van Erpecum KJ; van Berge-Henegouwen GP
World J Gastroenterol; 2005 Jan; 11(1):7-16. PubMed ID: 15609388
[TBL] [Abstract][Full Text] [Related]
56. Bile duct disorders.
Geubel AP; Sempoux C; Rahier J
Clin Liver Dis; 2003 May; 7(2):295-309. PubMed ID: 12879985
[TBL] [Abstract][Full Text] [Related]
57. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
58. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
Paumgartner G
World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
[TBL] [Abstract][Full Text] [Related]
59. Mechanism of hepatoprotective action of bile salts in liver disease.
Stiehl A; Benz C; Sauer P
Gastroenterol Clin North Am; 1999 Mar; 28(1):195-209, viii. PubMed ID: 10198785
[TBL] [Abstract][Full Text] [Related]
60. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]